Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Emily Chew is an Ophthalmologist in Bethesda, Maryland. Dr. Chew is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Retinopathy, and Cataract Removal.

Michael Elman is an Ophthalmologist in Baltimore, Maryland. Dr. Elman is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Retinal Vein Occlusion, and Vitrectomy. Dr. Elman is currently accepting new patients.

Elia J. Duh, M.D., is the G. Edward and G. Britton Durell Professor of Ophthalmology at the Wilmer Eye Institute. He has a joint appointment in the Department of Chemical and Biomolecular Engineering, The Whiting School of Engineering. He specializes in diseases of the retina, including diabetic retinopathy and age-related macular degeneration. In addition to his clinical practice, Dr. Duh actively researches the molecular mechanisms underlying diabetic retinopathy and macular degeneration, particularly the process of ocular neovascularization and excessive retinal vascular permeability. His research has helped determine the role of the major antioxidant regulator, Nrf2, in retinal diseases, and also connected Nrf2 to lifespan. His work has also provided insights into the involvement of the eye in COVID-19. Dr. Duh’s interest in developing new treatments for retinal diseases includes nanomedicine approaches for targeted drug delivery to the eye. Dr. Duh graduated summa cum laude from Yale University and obtained his medical degree from Harvard Medical School. He completed his ophthalmology residency and medical retina fellowship at the Wilmer Eye Institute. He was elected to the American Society of Clinical Investigation in 2016. Dr. Duh is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Vitrectomy.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy.

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

Cindy X. Cai, M.D., is the Jonathan and Marcia Javitt Rising Professor of Ophthalmology and a retina specialist seeing patients at the Wilmer Eye Institute’s locations in the Baltimore, Maryland area. Her primary focuses are in medical and surgical retina treatments, including: diabetic retinopathy, diabetic macular edema, age-related macular degeneration, retinal vascular occlusion, retinal detachment, vitreous hemorrhage, epiretinal membrane, and macular hole, among others. Dr. Cai graduated summa cum laude with a major in biology at Columbia University and received her M.D. from the Columbia University College of Physicians and Surgeons in New York. She completed her medical internship at Mercy Medical Center in Baltimore and her ophthalmology residency training at the Wilmer Eye Institute. She received her vitreoretinal surgery fellowship training at Duke Eye Center. Videos Dr. Cindy X. CaiOphthalmologist and Retina Specialist Recent News Articles and Media Coverage Continuing the Mission, Johns Hopkins Medicine (Dec. 2021) Get to Know Cindy Cai, Wilmer Insider (Apr. 2021). Dr. Cai is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Diabetic Retinopathy, Diabetic Macular Edema (DME), Gyrate Atrophy of the Choroid and Retina, Vitrectomy, and Cataract Removal.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Allen Hu is an Ophthalmologist in Cumberland, Maryland. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Geographic Atrophy, Diabetic Retinopathy, and Vitrectomy.

Rohit Lakhanpal is an Ophthalmologist in Baltimore, Maryland. Dr. Lakhanpal is rated as a Distinguished provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Late-Onset Retinal Degeneration, Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Retinal Artery Occlusion, and Vitrectomy. Dr. Lakhanpal is currently accepting new patients.

Dr. Sudipa Sarkar is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include endocrinology. She received her M.D. from Yale School of Medicine. She completed her residency in internal medicine at Yale-New Haven Hospital and performed a fellowship in endocrinology, diabetes and metabolism at Vanderbilt University Medical Center. Dr. Sarkar joined the Johns Hopkins faculty in 2017. Dr. Sarkar is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Type 2 Diabetes (T2D), Diabetic Retinopathy, Maturity Onset Diabetes of the Young, Diabetic Neuropathy, and Sleeve Gastrectomy.

Sharon D. Solomon, M.D., is the Katharine M. Graham Professor of Ophthalmology at the Wilmer Eye Institute. A retina specialist and ophthalmologist, Dr. Solomon's clinical expertise includes medical and surgical treatment of age-related macular degeneration, diabetic retinopathy, epiretinal membranes, macular holes, and retinal tears and detachment. Dr. Solomon has a large national and international referral practice at Wilmer. Dr. Solomon has served as principal investigator at Wilmer on a number of NIH-sponsored clinical trials. She has numerous publications from her clinical trials involvement. Dr. Solomon received her bachelor's degree in biochemistry from Harvard University and her medical degree from the University of California, San Francisco. After her internship at Stanford, she returned to UCSF for her residency in ophthalmology. Dr. Solomon completed her surgical retina fellowship at the Wilmer Eye Institute prior to joining the faculty. Dr. Solomon is a member of the prestigious Miller-Coulson Academy of Clinical Excellence at Johns Hopkins. Dr. Solomon is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Gyrate Atrophy of the Choroid and Retina, and Vitrectomy.

Mira M. Sachdeva, M.D., Ph.D. specializes in the medical and surgical management of diseases of the retina, including diabetic retinopathy, macular degeneration, retinal vascular occlusions, retinal detachments, macular holes, and epiretinal membranes. Her research efforts are directed towards developing new treatments to prevent or reverse the retinal neurodegeneration and vision loss that occurs in patients with diabetes. Dr. Sachdeva’s ultimate goal is to identify strategies for neuroprotection that are broadly applicable to other conditions in which the retina is irreversibly damaged, including macular degeneration and retinal detachment. Dr. Sachdeva received her medical degree from the University of Pennsylvania medical school. She completed her residency at the Wilmer Eye Institute in 2014. Thereafter, she completed a fellowship at the Massachusetts Ear and Eye Infirmary. Dr. Sachdeva is currently a Wilmer Rising Professor in Ophthalmology. Videos Dr. SachdevaOphthalmology Recent News Articles and Media Coverage Bridging the Gap, Wilmer Magazine (July 2019). Dr. Sachdeva is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Diabetic Retinopathy, Retinal Detachment, Adult-Onset Vitelliform Macular Dystrophy (AVMD), Late-Onset Retinal Degeneration, and Vitrectomy.

Fernando Arevalo is an Ophthalmologist in Baltimore, Maryland. Dr. Arevalo is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Gyrate Atrophy of the Choroid and Retina, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Diabetic Retinopathy.

"Dr. Shah is an AUPO-fellowship trained ophthalmologist specializing in diseases of the retina, macula, and vitreous. A Pennsylvania native, Dr. Shah attended college at West Chester University of Pennsylvania. He later earned his medical degree at Drexel University College of Medicine and remained there to pursue his residency in Ophthalmology where he was also honored to serve as Chief Resident. Dr. Shah then pursued his fellowship training in vitreoretinal surgery at the Associated Retina Consultants in Phoenix, Arizona. Dr. Shah has been privileged to author or co-author over 40 book chapters and topics as well as publish scientific articles in peer-reviewed journals. He has been invited to lecture both physicians and students on current clinical issues. As a resident, he received multiple honors including Intern of the Year, Resident of the Year, and the Golden Apple for Teaching by the College of Medicine. He was even bestowed with Hahnemann University Hospital's highest award for training physicians – ""Excellence in Clinical Practice for a Fellow, Resident, or Intern."" Dr. Shah enjoys all aspects of retinal disease, but has particular interests in the management of acute, subacute, and chronic retinal disorders including age-related macular degeneration, diabetic retinopathy, and complex retinal detachments. Dr. Shah is a member of the American Society of Retinal Specialists and the American Academy of Ophthalmology.". Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Orbital Cellulitis, Hyphema, Kallikrein Hypertension, and Optic Nerve Atrophy.

Adrienne W. Scott, M.D, is a retina specialist and the Fred M. Leader Family Retina Professor of ophthalmology at the Wilmer Eye Institute's locations in Baltimore and Bel Air, Maryland. Dr. Scott treats patients across the spectrum of vitreoretinal medical and surgical diseases, including macular degeneration, diabetic retinopathy, retinal detachments and more. Dr. Scott received her doctor of medicine degree from Drexel University College of Medicine in Philadelphia, Pennsylvania and completed her ophthalmology residency at the Duke University Eye Center. During her residency, Dr. Scott received the Ocular Innovation Award, the K. Alexander Dastgheib Eye Surgery Award and the Edward K. Isbey, Jr. M.D. Award for clinical excellence. She remained at the Duke Eye Center to complete her two-year fellowship training in vitreoretinal surgery prior to joining the Wilmer faculty. Dr. Scott is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. Her top areas of expertise are Retinal Detachment, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Diabetic Retinopathy.

Peter L. Gehlbach, M.D., Ph.D. is the J. Willard Marriott, Jr. Professor of Ophthalmology with joint appointment in the Department of Electrical and Computer Engineering, The Whiting School of Engineering. A member of the Wilmer faculty since 2000, he was recruited by a national search to become the inaugural Maumenee Scholar at Johns Hopkins University School of Medicine. His clinical practice is composed of international, national, and regional patient populations with the most complex retinal disease. An expert vitreoretinal surgeon, Dr. Gehlbach has been a leader in performing and teaching complex surgical cases that require coordination with multiple ophthalmological specialists. His research interests include cutting-edge surgical approaches to patients with retinal disease and the development of novel surgical tools and approaches to retinal microsurgery. Dr. Gehlbach’s work has been supported by multiple NIH grants and prestigious foundations with research published in numerous peer-reviewed journals and presented at ophthalmology conferences around the world. The founding director of the former Wilmer Gene Therapy Vector Center, he has served as the director of the Wilmer Echography Center as well as the Retina Fellowship Training Program at Johns Hopkins. He holds multiple patents in both the U.S. and abroad. Dr. Gehlbach received his B.A. and M.D. degrees from the University of Vermont, and his Ph.D. in cell and integrative physiology from the University of Minnesota. He completed an internship and residency training in general surgery at the University of Health Sciences, Chicago Medical School. His ophthalmology residency was at Washington University in St. Louis, where he also completed a fellowship in protein chemistry. He completed a medical and surgical retina fellowship at the Casey Eye Institute in Portland. Dr. Gehlbach is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Detachment, Retinal Vein Occlusion, and Vitrectomy.

Amir H. Kashani, M.D., Ph.D. is a retina specialist, surgeon, the Boone Pickens Professor in Ophthalmology and a professor in bioengineering treating patients at Wilmer Eye Institute’s East Baltimore and Columbia locations. Dr. Kashani specializes in the diagnosis and treatment of medical and surgical retinal diseases including diabetic retinopathy, retinal vein occlusions, age-related macular degeneration, epiretinal membranes and retinal detachments as well as other common retinal diseases. Dr. Kashani is an NIH-funded clinician-scientist studying the pathophysiology of retinal vascular diseases, such as diabetic retinopathy, vascular cognitive impairment and dementia in human patients using cutting-edge, noninvasive imaging methods such as optical coherence tomography angiography. He has co-authored more than 50 peer-reviewed articles in the scientific literature, several subject reviews, and an ophthalmology handbook titled Optical Coherence Tomography and OCT Angiography: Clinical Reference and Case Studies. Dr. Kashani is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Gyrate Atrophy of the Choroid and Retina, Diabetic Retinopathy, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD).

T. Y. Alvin Liu, M.D. is the James P. Gills, Jr. M.D., and Heather Gills Rising Professor of AI and the founding director of the Wilmer Precision Ophthalmology Center of Excellence. He is originally from Hong Kong, and speaks fluent Cantonese and Mandarin. He attended Phillips Exeter Academy in Exeter, New Hampshire, and graduated from Cornell University with a dual major in biology and economics. He received his M.D. from Columbia University in 2012, and completed his residency (2016) and fellowship (surgical and medical retina- 2018) at Johns Hopkins. He is subspecialty-trained in the medical and surgical treatment of vitreoretinal diseases, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vascular occlusion, retinal detachment, vitreous hemorrhage, epiretinal membrane and macular hole. Dr. Liu's research interests center on the application of artificial intelligence in the screening, diagnosis, prognostication and treatment of ophthalmic diseases, with a specific focus on vitreoretinal diseases such as age-related macular degeneration and diabetic retinopathy. In addition, he is involved in research on the pathogenesis of and treatment for pathologic myopia and the management of severe ocular trauma. Videos Dr. Tin Yan Alvin Liu Recent News Articles and Media Coverage AI Speeds Diabetic Retinopathy Diagnosis Without Specialist. Medscape August 28, 2018 AI Screening for Diabetic Retinopathy Moves to Retail Clinics. Medscape November 26, 2019 How Artificial Intelligence is Primed to Change Ophthalmology. Ophthalmology Advisor May 14, 2021 Medicine's first autonomous AI could prevent blindness due to diabetes. Stat News December 16, 2021 Innovations in Eye Care: How Technology is Transforming Ophthalmology. HealthTech November 29, 2022 Time to go multicultural. Retina Today March 1, 2023 How deep learning may play a role in predicting retinitis pigmentosa visual impairment. Ophthalmology Times March 14, 2023 AI in retinal diagnostics. Zhaoke Ophthalmology March 22, 2023 Macular Degeneration. Spotlight on Geographic Atrophy. Advances in Treatment. WebMD April 23, 2023 ARVO 2023: T.Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmology. Modern Retina April 25, 2023 ASCRS: Prediction of imminent conversion to neovascular AMD using deep learning and 3D OCT volumes. OptometryTimes May 5, 2023 Adopting and regulating AI in healthcare. BNN Bloomberg May 29, 2023 AI could increase health equity and boost adherence to annual eye examination in patients with diabetes. Modern Retina June 21, 2023 As more Marylanders grow older, a debilitating eye disease is gaining ground. The Baltimore Banner June 26, 2023. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Diabetic Retinopathy. His top areas of expertise are Usher Syndrome Type 2A, Cone Rod Dystrophy Amelogenesis Imperfecta, Cone-Rod Dystrophy, and Stargardt Macular Degeneration.